VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Porin and S-LPS Extracted from Virulent Brucella abortus 2308
Vaccine Information
  • Vaccine Name: Porin and S-LPS Extracted from Virulent Brucella abortus 2308
  • Target Pathogen: Brucella spp.
  • Target Disease: Brucellosis
  • Vaccine Ontology ID: VO_0000403
  • Type: Subunit vaccine
  • Antigen: The antigen for this vaccine is a complex of porin and smooth lipopolysaccharide (S-LPS) extracted from virulent Brucella abortus 2308 (Winter et al., 1988).
  • Adjuvant: MPL vaccine adjuvant
    • Adjuvant name: MPL vaccine adjuvant
    • VO adjuvant ID: VO_0001250
    • Description: The porin-S-LPS was given without adjuvant or in several adjuvants: trehalose dimycolate and muramyl dipeptide; the pluronic polymer L-121 and muramyl dipeptide; or complexed with Quil A in immunostimulating complexes (Winter et al., 1988).
  • Preparation: The S-LPS was produced from smooth strain 2308 by extraction in hot phenol followed by treatment with guanidinium thiocyanate. Inocula were prepared from a freshly thawed vial which was diluted in sterile phosphate buffered saline to yield an infecting dose of 5 x 104 bacteria per 0.1 ml. Each dose was mixed with its appropriate adjuvant (Winter et al., 1988).
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Five week-old female mice were used. The mice were vaccinated subcutaneously. Blood samples were taken on one or more occasions during the course of some experiments. Quantitative cultures for viable B. abortus were performed on spleens at 1 and 4 weeks postinfection. Each mouse was vaccinated with 30 micrograms of porin-S-LPS (Winter et al., 1988).
  • Immune Response: Protective vaccines caused the formation of increased concentrations of circulating O-polysaccharide-specific antibodies, although there were individual exceptions to the quantitative associatiQn between O-polysaccharide-specific antibodies and protection. Antibodies specific for porin or R-LPS were found in negligible quantities in vaccinated mice (Winter et al., 1988).
  • Challenge Protocol: B. abortus smooth strain 2308 of known virulence was used for challenge infections. In some experiments, vaccination or challenge was performed with vaccine strain 19. Animals were challenged 4 weeks postinfection with approximnately 5 x 104 CFU of live B. abortus cells (Winter et al., 1988).
  • Efficacy: Vaccination with porin-S-LPS conferred significant protection against challenge infections with either B. abortus 2308 or 19 at both 1 and 4 weeks postinfection. The magnitude of protection was not significantly enhanced at either time period by the inclusion of TDM and MDP adjuvant in the vaccine. In contrast, vaccination with the same quantity of porin-R-LPS with or without adjuvant provided no significant protection against either challenge strain (Winter et al., 1988).
References
Winter et al., 1988: Winter AJ, Rowe GE, Duncan JR, Eis MJ, Widom J, Ganem B, Morein B. Effectiveness of natural and synthetic complexes of porin and O polysaccharide as vaccines against Brucella abortus in mice. Infection and immunity. 1988; 56(11); 2808-2817. [PubMed: 2844673].